Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

Elizabeth Seiverling, Emmy M. Fernanadez, David Adams

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

Original languageEnglish (US)
Pages (from-to)368-369
Number of pages2
JournalJournal of drugs in dermatology : JDD
Volume5
Issue number4
StatePublished - Jan 1 2006

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.'. Together they form a unique fingerprint.

  • Cite this